Surgery and Hepatocellular Carcinoma

Overview

Journal Liver Cancer

Date 2016 Dec 21

PMID 27995087

Citations 27

Authors

Nobuhisa Akamatsu

Umberto Cillo

Alessandro Cucchetti

Matteo Donadon

Antonio Daniele Pinna

Guido Torzilli

Norihiro Kokudo

Affiliations

Soon will be listed here.

Abstract

The optimal surgical strategy for hepatocellular carcinoma (HCC) is under active debate. Bio-markers of the liver functional reserve as well as volumetric analysis of the future liver remnant are essential for safe liver resection of HCC. The present algorithms applied to surgical strategies for HCC are not ideal because many patients who could potentially undergo safe resection are deemed liver transplant candidates in Western countries, whereas the opposite is the case in Eastern countries. In addition, there is too much focus on expanded criteria for patients with HCC to undergo liver transplantation. The transplantation benefit for patients with HCC should be considered based not only on the individual's benefit, but also on the effect of other patients waiting for LT for other indications.

Citing Articles

NOL-7 serves as a potential prognostic-related biomarker for hepatocellular carcinoma.

Lei Q, Huang Y, Deng F, Zheng H, Hong X, Wang P Discov Oncol. 2025; 16(1):69.

PMID: 39836310 PMC: 11751243. DOI: 10.1007/s12672-024-01551-7.

The Comparative Metabolism of a Novel Hepatocellular Carcinoma Therapeutic Agent, 2,3-Diamino--(4-(benzo[d]thiazol-2-yl)phenyl)propanamide, in Human and Animal Hepatocytes.

Jung Y, Lee D, Kwon Y, Jang E, Choi G, Kim Y Metabolites. 2024; 14(8).

PMID: 39195521 PMC: 11356571. DOI: 10.3390/metabo14080425.

Is Transarterial Chemoembolization Only Treatment Option in Patients with Intermediate Stage of Hepatocellular Carcinoma?: in Perspectives of Surgery.

Lim J, Lee M, Kim T J Liver Cancer. 2023; 20(2):113-119.

PMID: 37384321 PMC: 10035680. DOI: 10.17998/jlc.20.2.113.

Impact of Oocyte Extract Supplement on Quality of Life after Hepatectomy for Liver Tumours: A Prospective, Multicentre, Double-Blind Randomized Clinical Trial.

Donadon M, Palmisano A, Bizzarri M, Ceriani R, Veneroni L, Donati G Cancers (Basel). 2023; 15(10).

PMID: 37345146 PMC: 10216542. DOI: 10.3390/cancers15102809.

Perioperative and long-term survival outcomes of laparoscopic versus open hepatectomy for BCLC stage A large hepatocellular carcinoma patients in difficult segments: A two-centre, propensity score matching analysis.

Ding D, Liu L, Lin K, Gan X, Guo X, Ding W Front Oncol. 2023; 13:1095357.

PMID: 36969010 PMC: 10038276. DOI: 10.3389/fonc.2023.1095357.

References

Ichikawa T, Uenishi T, Takemura S, Oba K, Ogawa M, Kodai S . A simple, noninvasively determined index predicting hepatic failure following liver resection for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2008; 16(1):42-8. DOI: 10.1007/s00534-008-0003-4. View

Teh S, Christein J, Donohue J, Que F, Kendrick M, Farnell M . Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. J Gastrointest Surg. 2005; 9(9):1207-15. DOI: 10.1016/j.gassur.2005.09.008. View

Torzilli G, Makuuchi M, Inoue K, Takayama T, Sakamoto Y, Sugawara Y . No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach. Arch Surg. 1999; 134(9):984-92. DOI: 10.1001/archsurg.134.9.984. View

Forner A, Llovet J, Bruix J . Hepatocellular carcinoma. Lancet. 2012; 379(9822):1245-55. DOI: 10.1016/S0140-6736(11)61347-0. View

Cucchetti A, Cescon M, Bertuzzo V, Bigonzi E, Ercolani G, Morelli M . Can the dropout risk of candidates with hepatocellular carcinoma predict survival after liver transplantation?. Am J Transplant. 2011; 11(8):1696-704. DOI: 10.1111/j.1600-6143.2011.03570.x. View

Han K, Kudo M, Ye S, Choi J, Poon R, Seong J . Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology. 2012; 81 Suppl 1:158-64. DOI: 10.1159/000333280. View

Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T . Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res. 2015; 45(2). DOI: 10.1111/hepr.12464. View

Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G . Reply to Letter: "Dissecting EASL/AASLD Recommendations With a More Careful Knife: A Comment on 'Surgical Misinterpretation' of the BCLC Staging System": Real Misinterpretation or Lack of Clarity Within the BCLC?. Ann Surg. 2013; 262(1):e18-9. DOI: 10.1097/SLA.0000000000000383. View

Chan S, Fan S . Selection of patients of hepatocellular carcinoma beyond the Milan criteria for liver transplantation. Hepatobiliary Surg Nutr. 2014; 2(2):84-8. PMC: 3924653. DOI: 10.3978/j.issn.2304-3881.2012.12.04. View

10.

Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G . A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. Ann Surg. 2013; 257(5):929-37. DOI: 10.1097/SLA.0b013e31828329b8. View

11.

Jung Y, Jung C, Seo Y, Kim J, Kim T, Yoo Y . BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A. J Gastroenterol Hepatol. 2015; 31(2):467-74. DOI: 10.1111/jgh.13152. View

12.

Vitale A, Ramirez Morales R, Zanus G, Farinati F, Burra P, Angeli P . Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. Lancet Oncol. 2011; 12(7):654-62. DOI: 10.1016/S1470-2045(11)70144-9. View

13.

Toso C, Mazzaferro V, Bruix J, Freeman R, Mentha G, Majno P . Toward a better liver graft allocation that accounts for candidates with and without hepatocellular carcinoma. Am J Transplant. 2014; 14(10):2221-7. DOI: 10.1111/ajt.12923. View

14.

Akamatsu N, Sugawara Y, Kokudo N . Living donor liver transplantation for patients with hepatocellular carcinoma. Liver Cancer. 2014; 3(2):108-18. PMC: 4057790. DOI: 10.1159/000343866. View

15.

Akamatsu N, Sugawara Y, Kokudo N . Living-donor vs deceased-donor liver transplantation for patients with hepatocellular carcinoma. World J Hepatol. 2014; 6(9):626-31. PMC: 4179141. DOI: 10.4254/wjh.v6.i9.626. View

16.

Cescon M, Colecchia A, Cucchetti A, Peri E, Montrone L, Ercolani G . Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma. Ann Surg. 2012; 256(5):706-12. DOI: 10.1097/SLA.0b013e3182724ce8. View

17.

Vitale A, Volk M, De Feo T, Burra P, Frigo A, Ramirez Morales R . A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. J Hepatol. 2013; 60(2):290-7. DOI: 10.1016/j.jhep.2013.10.010. View

18.

Cillo U, Vitale A, Volk M, Frigo A, Grigoletto F, Brolese A . The survival benefit of liver transplantation in hepatocellular carcinoma patients. Dig Liver Dis. 2010; 42(9):642-9. DOI: 10.1016/j.dld.2010.02.010. View

19.

Cucchetti A, Ercolani G, Vivarelli M, Cescon M, Ravaioli M, La Barba G . Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transpl. 2006; 12(6):966-71. DOI: 10.1002/lt.20761. View

20.

Cucchetti A, Vitale A, Cescon M, Gambato M, Maroni L, Ravaioli M . Can liver transplantation provide the statistical cure?. Liver Transpl. 2013; 20(2):210-7. DOI: 10.1002/lt.23783. View